| FDG- and amyloid-PET in Alzheimer's disease: is the whole greater than the sum of the parts? | |
| | |
MedLine Citation:
|
PMID: 21532539 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The development of prevention therapies for Alzheimer's disease (AD) would greatly benefit from biomarkers that are sensitive to subtle brain changes occurring prior to the onset of clinical symptoms, when the potential for preservation of function is at the greatest. In vivo brain imaging is a promising tool for the early detection of AD through visualization of abnormalities in brain structure, function and histopathology. Currently, positron emission tomography (PET) imaging with amyloid-beta (Aβ) tracers and 2-[(18)F]fluoro-2-Deoxy-D-glucose (FDG) is largely utilized in the diagnosis of AD. This paper reviews brain Aβ- and FDG-PET studies in AD patients as well as in non-demented individuals at risk for AD. We then discuss the potential of combining symptoms-sensitive FDG-PET measures with pathology-specific Aβ-PET to improve the early detection of AD. |
| | |
Authors:
|
L Mosconi; P F McHugh |
Related Documents
:
|
8956599 - Branchial pouch sinus tract from the piriform fossa causing acute suppurative thyroidit... 17536089 - Functional evaluations of the parotid and submandibular glands using dynamic magnetic r... 21464809 - Brain arteriovenous malformations: from diagnosis to treatment. 18246229 - Accuracy of single versus combined use of ultrasonography or computed tomography in the... 8790199 - Thallium-201 and iodine-131 scintigraphy in differentiated thyroid carcinoma. 9393259 - Cost utility of routine imaging with tc-99m-sestamibi in primary hyperparathyroidism be... 16186459 - Screening sexually active adolescents for chlamydia trachomatis: what about the boys? 8956599 - Branchial pouch sinus tract from the piriform fossa causing acute suppurative thyroidit... 21337419 - Chemical exchange saturation transfer (cest): what is in a name and what isn't? |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology Volume: 55 ISSN: 1824-4785 ISO Abbreviation: Q J Nucl Med Mol Imaging Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-05-02 Completed Date: 2011-09-20 Revised Date: 2012-03-07 |
Medline Journal Info:
|
Nlm Unique ID: 101213861 Medline TA: Q J Nucl Med Mol Imaging Country: Italy |
Other Details:
|
Languages: eng Pagination: 250-64 Citation Subset: IM |
Affiliation:
|
Department of Psychiatry, New York University School of Medicine, New York, NY 10016, USA. lisa.mosconi@nyumc.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aging / metabolism Alzheimer Disease / diagnosis, genetics, metabolism, radionuclide imaging* Amyloid beta-Peptides / metabolism Apolipoproteins E / genetics Brain / metabolism Dementia / diagnosis, metabolism, radionuclide imaging Diagnosis, Differential Fluorine Radioisotopes / diagnostic use Fluorodeoxyglucose F18 / diagnostic use Humans Positron-Emission Tomography Predictive Value of Tests Radiopharmaceuticals / diagnostic use |
| Grant Support | |
ID/Acronym/Agency:
|
AG032554/AG/NIA NIH HHS; AG13616/AG/NIA NIH HHS; AG35137/AG/NIA NIH HHS; M01 RR000096-42/RR/NCRR NIH HHS; M01-RR0096/RR/NCRR NIH HHS; R01 AG013616-20/AG/NIA NIH HHS; R01 AG013616-21/AG/NIA NIH HHS; R01 AG035137-03/AG/NIA NIH HHS; R21 AG032554-02/AG/NIA NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Amyloid beta-Peptides; 0/Apolipoproteins E; 0/Fluorine Radioisotopes; 0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The dynamic marker hypothesis of Alzheimer's disease and its implications for clinical imaging.
Next Document: Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease.